Steven Davanzo

Steven Davanzo serves as a key procurement lead within the W4PZ USA Medical Research Acquisition Act under the Department of the Army, overseeing the acquisition of advanced biomedical research and development services critical to warfighter health and readiness. He manages a portfolio of contracts focused on translating laboratory innovations into field-deployable diagnostics, therapeutics, and analytical tools, ensuring alignment with military medical priorities. His work bridges scientific discovery and operational capability, primarily facilitating non-clinical R&D contracts through competitive solicitation and technical evaluation processes. Davanzo’s acquisitions are strategically aligned with the Army’s long-term biomedical modernization goals, emphasizing rapid prototyping, translational science, and scalable solutions for austere environments. Davanzo’s contractor relationships are broadly distributed across academic research institutions, private biotechnology firms, and specialized engineering service providers engaged in life sciences R&D. He cultivates partnerships with entities capable of delivering high-complexity, mission-critical research outputs under stringent federal compliance standards. While no single contractor dominates his portfolio, his procurement patterns reflect a preference for organizations with proven expertise in molecular diagnostics, bioinformatics, and medical countermeasure development. His approach emphasizes technical merit, past performance, and the ability to meet rapid development timelines without compromising scientific rigor. Davanzo’s contracting activity is entirely non-set-aside, with 100% of awards issued under full and open competition. This reflects a deliberate strategy to prioritize technical capability and innovation over socioeconomic preferences, ensuring access to the broadest possible pool of qualified research entities. While small business participation is not mandated through set-asides, he actively evaluates proposals from small firms based on technical merit and capacity, maintaining a neutral but inclusive procurement posture. His primary focus is on NAICS 541715—Research and Development in the Physical, Engineering, and Life Sciences—encompassing preclinical studies, biomarker discovery, point-of-care diagnostics, and advanced analytical platforms. He procures services involving in vitro and in vivo modeling, genomic sequencing, data analytics for medical surveillance, and prototype device validation, demonstrating deep expertise in the intersection of biomedical science and defense acquisition.